Login
$CELC
$60.57 -$3.80 (5.9%) Live

$CELC SEC Filings

Filed On Filing
16 Nov 2026 SCHEDULE 13G/A
16 Nov 2026 SCHEDULE 13G/A
05 Nov 2026 10-Q
05 Nov 2026 8-K: Results of Operations and Financial Condition

REVTORPYK became commercially available on September 30th for the treatment of patients with HR+/HER2- PIK3CA wild-type locally advanced or metastatic breast cancer

09 Oct 2026 Form 4: Furcht Leo, Director

Received 250 shares by exercise or conversion ($1.9K)

05 Oct 2026 Form 4: Gryska David W, Director

Received 893 shares as a grant or award

05 Oct 2026 Form 3: Gryska David W, Director

No securities owned

02 Oct 2026 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

Mr. Gryska brings decades of strategic and financial leadership experience to Celcuity’s Board

30 Sep 2026 8-K: Regulation FD Disclosure; Other Events

REVTORPYK is indicated for patients with HR+/HER2- advanced breast cancer without a PIK3CA mutation detected following progression on or after at least one line of endocrine therapy in the metastatic setting

26 Aug 2026 8-K: Regulation FD Disclosure; Other Events

Celcuity Submits sNDA to FDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer

18 Aug 2026 Form 4: Sullivan Brian F., Director

Received 80,000 shares as a grant or award · Granted 120,000 Performance Stock Units

18 Aug 2026 Form 4: Laing Lance G., Director

Received 20,000 shares as a grant or award · Granted 10,000 Performance Stock Units

18 Aug 2026 Form 4: Hahne Vicky, Chief Financial Officer

Received 16,000 shares as a grant or award · Granted 10,000 Performance Stock Units

13 Aug 2026 10-Q
13 Aug 2026 8-K: Results of Operations and Financial Condition

REVTORPYK™ (gedatolisib) approved by the U.S. FDA for the treatment of HR+/HER2- PIK3CA Wild-Type locally advanced or metastatic breast cancer on July 14, 2026; on track for commercial launch late third quarter 2026

11 Aug 2026 SCHEDULE 13G
16 Jul 2026 SCHEDULE 13G
16 Jul 2026 SCHEDULE 13D/A
16 Jul 2026 Form 4: Baker Bros. Advisors Lp, Former 10% owner and 3 others

Sold 3,100,000 shares ($318M)

15 Jul 2026 8-K/A: Regulation FD Disclosure; Other Events

Celcuity Announces FDA Approval of REVTORPYK™ (gedatolisib) for the Treatment of HR+/HER2-, PIK3CA Wild-Type Locally Advanced or Metastatic Breast Cancer

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support